Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial

This publication has 22 references indexed in Scilit:

• Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial InfarctionA Randomized Controlled Trial
  JAMA, 2005
• Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
  Journal of the American College of Cardiology, 2004
• Beneficial Effect of Intracoronary Verapamil on Microvascular and Myocardial Salvage in Patients With Acute Myocardial Infarction
  Journal of the American College of Cardiology, 1997
• Rapid reversal of no-reflow using abciximab after coronary device intervention
  Catheterization and Cardiovascular Diagnosis, 1997
• Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine
  American Heart Journal, 1996
• Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin
  Catheterization and Cardiovascular Diagnosis, 1996
• Clinical Implications of the ‘No Reflow’ Phenomenon
  Circulation, 1996
• Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.
  Circulation, 1994
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction.
  Circulation, 1992